Patent Update: Oncologic, Endocrine & Metabolic Small molecule inhibitors of tyrosine kinase activity

References

• SPENCE P: Inhibitors of tyrosine kinase activity as anti-cancer therapeutics: recent developments. Curr. Opin. Thera. Patents (1993) 1: 3–9.
   Google Scholar
• FRY DW: Protein tyrosine kinases as therapeutic targetsIn cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs (1994) 3: 577–595.
   Google Scholar
• LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: anapproach to drug development. Science ( 1995) 267: 1782–1788.
   PubMed Web of Science ®Google Scholar
• BOUTIN JA: Tyrosine kinase inhibition and cancer. Int. J. Biochem. (1994) 26: 1203–1226.
   PubMedGoogle Scholar
• BURKE TR, Jr.: Protein-tyrosine kinases: potential targets for anticancer drug development. Stem Cells (1994) 12: 1–6.
   PubMedGoogle Scholar
• SRINIVAS PR, GRUNBERGER G: Inhibitors of the insulin receptor tyrosine kinase. Pharmacol. Ther. (1994) 64: 23–35.
   PubMed Web of Science ®Google Scholar
• BLJRKE TR, Jr.: Protein-tyrosine kinase inhibitors. Drugs Future 0992) 17: 119–131.
   Google Scholar
• DOHERTY AM, KEISER JA: Growth factors in cardiovas-cular disease. Annu. Rep. Med. Chem. (1993) 28: 89–98.
   Google Scholar
• Trends Biochem. Sciences (1994) 19(11).
   Google Scholar
• Anti-Cancer Drug Research (1994) 9: 263–351.
   Google Scholar
• Cell (1995) 80: 2.
   Google Scholar
• KNIGHTON DR, CADENA DL, ZHENG J, TEN EYCK LF, TAYLOR SS, SOWADSKI JM, GILL GN et al.: Structural features that specify tyrosine kinase activity deduced from homology modelling of the epidermal growth factor receptor. Proc. Natl. Acad. Sci. (1993) 90: 5001–5005.
   PubMedGoogle Scholar
• HUBBARD SR, WET L, ELLIS L, HENDRICKSON WA: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (1994) 372: 746–754.
   PubMed Web of Science ®Google Scholar
• KOVALENKO M, GAZIT A, BOHMER A, RORSMAN C, HELDIN C-1f, WALTENBERGER J, BOHMER FD, LEVITZKI A: Selective platelet-derived growth factor receptor ki-nase blockers reverse sis-transformation. Cancer Res. (1994) 54: 61136–6114.
   Google Scholar
• Zeneca and Sugen extend collaboration. Scrip (1995) Jan.17th: 9.
   Google Scholar
• US biotechnology Co. Sugen initial public offering...Scrip (1994) Nov. 8th: 15.
   Google Scholar
• WARD WHJ, COOK PN, SLATER AM, DAVIES DH, HOLDGATE GA, GREEN LR: Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol (1994) 48: 659–666.
   Google Scholar
• 13UCHDUNGER E, TRINKS U, METE H, RENEGASS U,MULLER M, MEYER T, MCGLYNN E, PINNA LA, TRAXLER P, LYDON NB: 4,5-Dianilinophthalimide: a protein tyro-sine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. (1994) 91: 2334–2338.
   Google Scholar
• TRINKS U, BUCHDUNGER E, FURET P, KUMP W, METE H,MEYER T, MULLER M, REGENASS U, RIHS G, LYDON NB, TRAXLER P: Dianilinophthalimides: potent and selec-tive, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. (1994) 37: 1015–1027.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, ZIMMERMAN J, METT H, MEYER T, MULLER M, REGENASS U, LYDON NB: Selective inhibition of the platelet-derived growth factor signal transduc-tion pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyritnidine class. Proc. Natl. Acad. Sci. (1995) 92: 2558–2562.
   PubMed Web of Science ®Google Scholar
• YONEDA T, LYALL RM, ALSINA MM, PERSONS PE, SPADAAP, LEVITZKI A: The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squatnous cell carcinoma in vitro and in nude mice. Cancer Res. (1991) 51: 4430–4435,
   PubMed Web of Science ®Google Scholar
• SLIDER GE, KASIEWSKI Cl, WALCZAK ME, PERRONE MH:PDGF-receptor protein tyrosine kinase activity in ca-rotid artery is enhanced by injury and inhibited in vivo by tyrphostin RG-13291. Drug Dev. Res. (1993) 29: 158.
   Google Scholar
• MAGLTIRE MP, SHEETS KR, MCVETY K, SPADA AP, ZILBER-STEIN A: A new series of PDGF receptor tyrosine kinase Inhibitors: 3-substituted quinoline derivatives. J. Med. Chem. (1994) 37: 2129–2137.
   PubMedGoogle Scholar
• CHEN H, BOIZIAU J, PARKER F, MAILL1ET P, COMMERCONA, TOCQUE B, LE PECQ J-B, ROQUES B-P, GARBAY C: Structure-activity relationships in a series of 5-[(2,5-di-hydroxybenzyDamino] salicylate Inhibitors of EGF-re-ceptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interaction. J. Med. Chem. (1994) 37: 845–859.
   PubMedGoogle Scholar
• CHEN H, BIOZIAU J, PARKER F, MAROUN R, TOCQUE B,ROQUES B, GARBAY-JAUREGUIBERRY C- Synthesis and structure activity of a series of Rhydroxyben-zyDatninolsalicylates as inhibitors of EGF receptor as-sociated tyrosine kinase activity.]. Med. Chem. (1993)36: 4094–4098.
   PubMed Web of Science ®Google Scholar
• DOW LR, CHOU TT, BECHLE BM, GODDARD C, LARSONER: Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibi-tors.]. Med. Chem. (1994) 37: 2224–2231.
   PubMedGoogle Scholar
• DOW LR, BECHLE BM, CHOU TT, GODDARD C, LARSONER: Selective inhibition of the tyrosine kinase pp6Osrc by analogs of 5,10-dihydropyrimido[4,5-b] quinolin-4(110-one. Biorg. & Med. Chem. Lett. (1995) 5: 1007–1010.
   Google Scholar
• PALMER BD, REWCASTLE GW, THOMPSON AM, BOYD M,SHOWALTER IIDH, SERCEL AD, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inhibitors. 4. Structure-ac-tivity relationships among n- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and non-receptor protein tyrosine !atlases. J. Med. Chem. (1995) 38: 58–67.
   Google Scholar
• FRY DW, KRAKER AJ, CONNERS RC, ELLIOT WL, NELSONJM, HOLLIS SHOWALTER HD, LEOPOLD WR: Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design (1994) 9: 331–351.
   PubMedGoogle Scholar
• REWCASTLE GW, PALMER BD, DOBRUS1N ME, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inharitors. 3. Structure-activity relationships for inhibition of pro-tein tyrosine kinases by nuclear-substituted derivatives of2, 2'-dithiobis (1-methyl-n-phe nyl-1 H- indole-3- car-boxamide). J. Med. Chem. (1994) 37: 2033–2042.
   Google Scholar
• THOMPSON AM, REWCASTLE GW, TERCEL M, DOBRUSIN ME, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inhibitors. 1. Structure activity relationships for inhibi-tion of epidermal growth factor receptor tyrosine ki-nase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alltanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids). J. Med. Chem. (1993) 36: 2459–2469.
   Google Scholar
• FRY DW, KRAKER AJ, MCMICHAEL A, AMBROSO LA, NELSON JM, LEOPOLD WR, CONNERS RC, BRIDGES AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (1994) 265: 1093–1095.
   PubMed Web of Science ®Google Scholar
• SUN L, SHOWALTER HDH, KRAKER AJ: Synthesis and biological evaluation of novel pyrroloquinazolinones as potent epidermal growth factor receptor tyrosine kinase inhibitors. 209th ACS National Meeting, (1995), Anaheim, CA: MEDI 036.
   Google Scholar
• DOLLE RE, DUNN JA, BOBKO M, SINGH B, KUSTER JE,BAIZMAN E, HARRIS AL, SAWUTZ DG, MILLER D, WANG S, FALTYNEK CR, XIE W, SARLT J, BODE DC, PAGANI ED, SILVER PJ: 5,7-Dimethoxy-3-(4-pyridinyDquinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. I Med. Chem. (1994) 37: 2627–2629.
   PubMedGoogle Scholar
• FALTYNEK CR, WANG S, MILLER D, MAUVAIS P, GAUVINB, REID J, XIE W, HOEKSTRA S, JUNIEWICZ P, SARUP J, LEHR R, SAWUTZ DG, MURPHY D: Inhibition of T lym-phocyte activation by a novel p561ck tyrosine kinase inhibitor. J. Enzyme Inhibition (1995) 9: 111–122.
   Google Scholar
• BUZZETFI F, BRASCA MG, CRUGNOLA A, FUSTINONI S,LONGO A, PENCO S, ZONCA PD, COMOGLIO PM: Cin-namide analogues as inhibitors of protein tyrosine kinases. Farmaco. (1993) 48: 615–636.
   PubMedGoogle Scholar
• BURKE TR, Jr., FORD H, OSHEROV N, LEVITZKI A, STE-FANOVA I, HORAK ID, MARQUEZ VE: Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors. Biorg. & Med. Chem. Lett. (1992) 2: 1771–1774.
   Google Scholar
• SMYTH MS, STEFANOVA I, HARMANN F, HORAK ID, OSHEROV N, LEVITZKI A, BURKE TR, Jr.: Non-amine based analogues of Lavendustin A as protein-kinase inhibi-tors J. Med. Chem. (1993) 36: 3010–3014.
   Google Scholar
• SMYTH MS, STEFANOVA N, HORAK ID, BURKE TR, Jr.: Hydroxylated 2-(5'-salicylnaphthalenes as protein tyro-sine kinase inhibitors J. Med. Chem. (1993) 36: 3015–3020.
   Google Scholar